Klaus Veitinger - Tricida Independent Chairman of the Board

TCDA -- USA Stock  

  Downward Rally

Dr. Klaus R. Veitinger M.D., Ph.D., is Independent Chairman of the Board of the Company. He has served as a member of our board of directors since February 2014 and as our Chairman of the Board since September 2015. Dr. Veitinger has served as a Venture Partner with OrbiMed Advisors LLC, an affiliate of one of our principal stockholders, since October 2007. Prior to OrbiMed Advisors, Dr. Veitinger was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma, Inc. with responsibility for the U.S. and Asia businesses. Dr. Veitinger has served on the boards of public companies, including Intercept Pharmaceuticals, Inc. from August 2012 until July 2016 and Relypsa, Inc. from October 2010 until June 2015, and currently serves on the board of scPharmaceuticals, Inc. since November 2017. Dr. Veitinger currently serves on the boards of directors of the following private companies Neurogastrx, Inc. and Promentis Pharmaceuticals, Inc. For seven years he was a Director of PhRMA
Age: 56  Chairman Since 2015  MBA    
415-429-7800  http://www.tricida.com
Veitinger received his M.D. and his Ph.D. from the University of Heidelberg. He earned his M.B.A. at INSEAD in France.

Klaus Veitinger Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (34.97) % which means that it has lost $34.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (72.61) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 39.5 M in liabilities with Debt to Equity (D/E) ratio of 11.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Tricida has Current Ratio of 13.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 12 records


Joseph PapaPerrigo Company Plc
Fredric EshelmanThe Medicines Company
Clive MeanwellThe Medicines Company
Rodney PiattMylan NV
Masahiro SakaneTakeda Pharmaceutical Company L
Chinh ChuCatalent
Marry BrlasPerrigo Company Plc
Masayo TadaSumitomo Dainippon Pharma Ltd
Said DarwazahHikma Pharmaceutical
Robert CouryMylan NV
Mazen DarwazahHikma Pharmaceutical

Entity Summary

Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease . Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California. Tricida operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 90 people.Tricida (TCDA) is traded on BATS Exchange in USA and employs 90 people.

Tricida Leadership Team

Jerry Buysse, Senior Vice President Chief Scientific Officer
Wilhelm Stahl, Senior Vice President CTO
Robert Alpern, Independent Director
Edward Hejlek, Senior Vice President General Counsel
Geoffrey Parker, CFO, Senior Vice President
David Hirsch, Independent Director
Claire Lockey, Senior Vice President and Chief Development Officer
David Bonita, Chairman of the Board
Sandra Coufal, Independent Director
Gerrit Klaerner, President CEO, Member of the Board of Directors
Jeroen Beek, Chief Commercial Officer and Senior Vice President
Kathryn Falberg, Independent Director
Klaus Veitinger, Independent Chairman of the Board
Dawn Parsell, Senior Vice President - Clinical Development
Susannah Cantrell, Senior Vice President Chief Commercial Officer

Stock Performance Indicators

Current Sentiment - TCDA

Tricida Investor Sentiment

Macroaxis portfolio users are evenly split in their outlook on investing in Tricida. What is your outlook on investing in Tricida? Are you bullish or bearish?
50% Bullish
50% Bearish

Currently Active Assets on Macroaxis

Purchased over 70 shares of
few hours ago
Traded for 36.89
Purchased few shares of
few hours ago
Traded for 163.21
Purchased over 70 shares of
few hours ago
Traded for 36.89
Purchased over 300 shares of
few hours ago
Traded for 8.95
Purchased over 40 shares of
few hours ago
Traded for 65.72
Also please take a look at World Market Map. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Search macroaxis.com